Analysts’ Recommendations for Johnson & Johnson on April 16
Wall Street analysts’ estimates
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
Interested in AMGN? Don't miss the next report.
Receive e-mail alerts for new research on AMGN
The above chart shows analysts’ recommendations in the past 12 months.
Johnson & Johnson’s stock price has decreased nearly 6.5% in the last 12 months. Analysts estimate that the stock might increase 13.8% in the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $148.67 per share—compared to the last price of $130.62 per share as of April 13, 2018.
As of April 16, 2018, there are 23 analysts tracking Johnson & Johnson. Five analysts recommend a “strong buy,” seven analysts recommend a “buy,” eight analysts recommend a “hold,” two analysts recommend a “sell,” and one analyst recommends a “strong sell.” The consensus rating for Johnson & Johnson stands at 2.43, which represents a moderate “buy” for value investors.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!